A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06163898 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Multiple Myeloma

Interventions

DRUG: Alnuctamab
DRUG: Mezigdomide
DRUG: Dexamethasone

Sponsor

Celgene